Preclinical and clinical assessment of the safety and potential efficacy of thalidomide in heart failure

Journal of Cardiac Failure

Volumn 8, Issue 5, 2002, Pages 306-314

  Agoston, Ildiko ^a   Dibbs, Ziad I ^a   Wang, Feng ^a   Muller, George ^b   Zeldis, Jerome B ^b   Mann, Douglas L ^a   Bozkurt, Biykem ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b CELGENE CORPORATION   (United States)

Author keywords

Cardiac myocytes; Heart failure; Thalidomide; Thalidomide analogues; TNF

Indexed keywords

3 (4 AMINO 1,3 DIHYDRO 1,3 DIOXO 2H ISOINDOL 2 YL)GLUTARIMIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CC 3089; CC 3098; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; INTERLEUKIN 10; LIPOPOLYSACCHARIDE; THALIDOMIDE; THALIDOMIDE DERIVATIVE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; UNCLASSIFIED DRUG;

ACUTE KIDNEY FAILURE; ADULT; ARTICLE; BRADYCARDIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GASTROENTERITIS; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE CELL; HUMAN; HUMAN CELL; HYPERKALEMIA; INFLAMMATION; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; RASH; SYNCOPE; TERATOGENICITY; WALKING;

EID: 0036774209     PISSN: 10719164     EISSN: None     Source Type: Journal    
DOI: 10.1054/jcaf.2002.128684     Document Type: Article

References (34)

1. Levine B, Kalman J, Mayer L, Fillit HM, Packer M: Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990;323(4):236-241
2. Kapadia SR, Yakoob K, Nader S, Thomas JD, Mann DL, Griffin BP: Elevated circulating levels of serum tumor necrosis factor-alpha in patients with hemodynamically significant pressure and volume overload. J Am Coll Cardiol 2000;36(1):208-212
3. Deswal A, Petersen NJ, Feldman AM, Young JB, White BG, Mann DL: Cytokines and cytokine receptors in advanced heart failure: An analysis of the cytokine database from the Vesnarinone Trial (VEST). Circulation 2001;103(16):2055-2059
4. Ferrari R, Bachetti T, Confortini R, Opasich C, Febo O, Corti A, Cassani G, Visioli O: Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure. Circulation 1995;92(6):1479-1486
5. Bozkurt B, Kribbs SB, Clubb FJ, Jr., Michael LH, Didenko VV, Hornsby PJ, Seta Y, Oral H, Spinale FG, Mann DL: Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats. Circulation 1998;97(14):1382-1391
6. Bradham WS, Bozkurt B, Gunasinghe H, Mann D, Spinale FG: Tumor necrosis factor-alpha and myocardial remodeling in progression of heart failure: A current perspective. Cardiovasc Res 2002;53(4):822-830
7. Sliwa K, Skudicky D, Candy G, Wisenbaugh T, Sareli P: Randomised investigation of effects of pentoxifylline on left-ventricular performance in idiopathic dilated cardiomyopathy. Lancet 1998;351(9109):1091-1093
8. Wagner DR, McTiernan C, Sanders VJ, Feldman AM: Adenosine inhibits lipopolysaccharide-induced secretion of tumor necrosis factor-alpha in the failing human heart. Circulation 1998;97(6):521-524
9. Parrillo JE, Cunnion RE, Epstein SE, Parker MM, Suffredini AF, Brenner M, Schaer GL, Palmeri ST, Cannon RO, III, Ailing D: A prospective, randomized, controlled trial of prednisone for dilated cardiomyopathy. N Engl J Med 1989;321(16):1061-1068
10. Deswal A, Bozkurt B, Seta Y, Parilti-Eiswirth S, Hayes FA, Blosch C, Mann DL: Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure. Circulation 1999;99(25):3224-3226
11. Bozkurt B, Torre-Amione G, Warren MS, Whitmore J, Soran OZ, Feldman AM, Mann DL: Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure. Circulation 2001;103(8):1044-1047
12. Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G: Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 1993;177(6):1675-1680
13. Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G: Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 1991;173(3):699-703
14. Powell RJ: New roles for thalidomide. BMJ 1996;313(7054):377-378
15. Amato RJ: Thalidomide: An antineoplastic agent. Curr Oncol Rep 2002;4(1):56-62
16. Ginsburg PM, Dassopoulos T, Ehrenpreis ED: Thalidomide treatment for refractory Crohn's disease: A review of the history, pharmacological mechanisms and clinical literature. Ann Med 2001;33(8):516-525
17. Stirling D: Thalidomide: A novel template for anticancer drugs. Semin Oncol 2001;28(6):602-606
18. Corral LG, Kaplan G: Immunomodulation by thalidomide and thalidomide analogues. Ann Rheum Dis 1999;58 suppl 1:1107-1113
19. Corral LG, Muller GW, Moreira AL, Chen Y, Wu M, Stirling D, Kaplan G: Selection of novel analogs of thalidomide with enhanced tumor necrosis factor alpha inhibitory activity. Mol Med 1996;2(4):506-515
20. Fujita J, Mestre JR, Zeldis JB, Subbaramaiah K, Dannenberg AJ: Thalidomide and its analogues inhibit lipopolysaccharide-mediated induction of cyclo-oxygenase-2. Clin Cancer Res 2001;7(11):3349-3355
21. Torre-Amione G, Kapadia S, Lee J, Durand JB, Bies RD, Young JB, Mann DL: Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation 1996;93(4):704-711
22. Yokoyama T, Vaca L, Rossen RD, Durante W, Hazarika P, Mann DL: Cellular basis for the negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian heart. J Clin Invest 1993;92(5):2303-2312
23. Schmidt-Choudhury A, Furuta GT, Lavigne JA, Galli SJ, Wershil BK: The regulation of tumor necrosis factor-alpha production in murine mast cells: Pentoxifylline or dexamethasone inhibits IgE-dependent production of TNF-alpha by distinct mechanisms. Cell Immunol 1996;171(1):140-146
24. Muller GW, Corral LG, Shire MG, Wang H, Moreira A, Kaplan G, Stirling DI: Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity. J Med Chem 1996;39(17):3238-3240
25. Jacobson JM, Greenspan JS, Spritzler J, Ketter N, Fahey JL, Jackson JB, Fox L, Chernoff M, Wu AW, MacPhail LA, Vasquez GJ, Wohl DA: Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med 1997;336(21):1487-1493
26. Marriott JB, Muller G, Dalgleish AG: Thalidomide as an emerging immunotherapeutic agent. Immunol Today 1999;20(12):538-540
27. Sampaio EP, Kaplan G, Miranda A, Nery JA, Miguel CP, Viana SM, Sarno EN: The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. J Infect Dis 1993;168(2):408-414
28. Corcoran C, Grinspoon S: Treatments for wasting in patients with the acquired immunodeficiency syndrome. N Engl J Med 1999;340(22):1740-1750
29. Koc S, Leisenring W, Flowers ME, Anasetti C, Deeg HJ, Nash RA, Sanders JE, Witherspoon RP, Appelbaum FR, Storb R, Martin PJ: Thalidomide for treatment of patients with chronic graft-versus-host disease. Blood 2000;96(12):3995-3996
30. Browne PV, Weisdorf DJ, DeFor T, Miller WJ, Davies SM, Filipovich A, McGlave PB, Ramsay NK, Wagner J, Enright H: Response to thalidomide therapy in refractory chronic graft-versus-host disease. Bone Marrow Transplant 2000;26(8):865-869
31. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M, Zeddis J, Barlogie B: Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999;341(21):1565-1571
32. Mantovani G, Maccio A, Massa E, Madeddu C: Managing cancer-related anorexia/cachexia. Drugs 2001;61(4):499-514
33. Davis MP, Dickerson ED: Thalidomide: Dual benefits in palliative medicine and oncology. Am J Hosp Palliat Care 2001;18(5):347-351
34. Peuckmann V, Fisch M, Bruera E: Potential novel uses of thalidomide: Focus on palliative care. Drugs 2000;60(2):273-292